To include your compound in the COVID-19 Resource Center, submit it here.

FDA, EMA, Japan reviewing Pfizer's lorlatinib for NSCLC

Pfizer Inc. (NYSE:PFE) said FDA accepted and granted Priority Review to an NDA

Read the full 136 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE